Pump.fun has introduced a perpetual futures trading interface powered by Hyperliquid, charging fees up to 0.10% per order and 0.25% per bridge transfer. The platform handles orders, margin, funding, liquidations, and settlements through Hyperliquid, but restricts access for users in the United States and Ontario. This new feature follows earlier product rollouts and offers leverage up to 40x for Bitcoin and 25x for Ether. The integration marks a significant expansion of Pump.fun’s trading offerings, while maintaining regulatory compliance by excluding certain regions.
Pump.fun's new Hyperliquid perpetuals launch provides context for cryptocurrency trading activity. For readers following the crypto market, here is Pluang's snapshot as of Oct 17, 2026 12:02 WIB: out of 50 major cryptocurrencies, 12 rose and 37 fell. Notable movers include VET at Rp125 with a 1-day change of -2.29% and a Pluang order activity split of 34% Sell / 66% Buy, ADA at Rp4.024 with a -2.09% change and 14% Sell / 86% Buy activity, and FTM at Rp11.382 down 2.05%.
Shares of MARA, a major Bitcoin mining company, fell sharply by 10.12% intraday to $7.48. This decline reflects a significant loss in the company's stock value during the trading session, distinct from the price of Bitcoin itself. The drop indicates ...
Deutsche Bank is set to begin offering custody services for bitcoin, ether, and three e-money tokens to institutional clients within weeks, starting in Germany. This service, pending regulatory approval, targets asset managers, corporations, and stat...
Bitcoin briefly fell below $80,000 before recovering above $82,000 amid inflation data and ETF flows. Ledger tightened reseller rules after discovering hardware implants used to steal recovery phrases, enhancing device security. MSCI introduced new e...
Evernorth Holdings announced partnerships with Ripple, Kraken, Coinbase, and BitGo to manage institutional strategies involving its 473 million XRP treasury. These collaborations are planned to begin deploying in the fourth quarter of 2026, pending c...
AbbVie unveiled 20 new scientific presentations at the 2026 United European Gastroenterology Week, highlighting long-term and real-world data for its inflammatory bowel disease (IBD) treatments SKYRIZI (risankizumab) and RINVOQ (upadacitinib). The da...
